PMID- 23237922
OWN - NLM
STAT- MEDLINE
DCOM- 20130722
LR  - 20221207
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 24
IP  - 3
DP  - 2013 Mar
TI  - Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with 
      advanced renal cell carcinoma.
PG  - 310-4
LID - 10.1097/CAD.0b013e32835c401c [doi]
AB  - The aim of this study was to evaluate the clinical factors, drug-related genetic 
      polymorphisms, and human leukocyte antigen (HLA) types to determine the 
      association with sorafenib-induced high-grade skin rash (HGSR) in Japanese 
      patients with advanced renal cell carcinoma (RCC). A total of 55 patients with 
      advanced RCC treated with sorafenib were analyzed retrospectively. Of these, 33 
      patients were subjected to HLA typing and polymorphism analyses of CYP3A5, ABCB1, 
      ABCC2, and UGT1A1, which are involved in the metabolism and membrane transport of 
      sorafenib. Grade 3 or higher SR developed in 12 (22%), and a higher incidence was 
      observed in female patients than in male patients (40 vs. 15%, P=0.046). The 
      initial dose, initial dose per body weight, and initial dose per body surface 
      area in patients with HGSR were significantly higher than those in patients 
      without HGSR. Patients with the ABCC2 -24CC genotype were at a significantly 
      higher risk of SR than those with the CT genotype (35 vs. 0%, P=0.032). HLA-A*24 
      was significantly associated with the occurrence of HGSR (P=0.049). Our finding 
      suggested that women, higher initial dose per body weight or body surface area, 
      the ABCC2 -24CC genotype, and HLA-A*24 are associated with the risk of 
      sorafenib-induced HGSR in Japanese RCC patients.
FAU - Tsuchiya, Norihiko
AU  - Tsuchiya N
AD  - Departments of Urology, Akita University Graduatae School of Medicine, Akita 
      010-8543, Japan.
FAU - Narita, Shintaro
AU  - Narita S
FAU - Inoue, Takamitsu
AU  - Inoue T
FAU - Hasunuma, Naoko
AU  - Hasunuma N
FAU - Numakura, Kazuyuki
AU  - Numakura K
FAU - Horikawa, Yohei
AU  - Horikawa Y
FAU - Satoh, Shigeru
AU  - Satoh S
FAU - Notoya, Takeshi
AU  - Notoya T
FAU - Fujishima, Naohito
AU  - Fujishima N
FAU - Hatakeyama, Shingo
AU  - Hatakeyama S
FAU - Ohyama, Chikara
AU  - Ohyama C
FAU - Habuchi, Tomonori
AU  - Habuchi T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ABCC2 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Multidrug Resistance-Associated Protein 2)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 1.14.14.1 (CYP3A5 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP3A)
RN  - EC 2.4.1.- (UGT1A1 enzyme)
RN  - EC 2.4.1.17 (Glucuronosyltransferase)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Asian People
MH  - Carcinoma, Renal Cell/*drug therapy/genetics/pathology
MH  - Cytochrome P-450 CYP3A/genetics
MH  - Dose-Response Relationship, Drug
MH  - Exanthema/*chemically induced
MH  - Female
MH  - Glucuronosyltransferase/genetics
MH  - HLA-A24 Antigen/*genetics
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Multidrug Resistance-Associated Protein 2
MH  - Multidrug Resistance-Associated Proteins/*genetics
MH  - Niacinamide/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Phenylurea Compounds/administration & dosage/*adverse effects/therapeutic use
MH  - Retrospective Studies
MH  - Sorafenib
EDAT- 2012/12/15 06:00
MHDA- 2013/07/23 06:00
CRDT- 2012/12/15 06:00
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/07/23 06:00 [medline]
AID - 10.1097/CAD.0b013e32835c401c [doi]
PST - ppublish
SO  - Anticancer Drugs. 2013 Mar;24(3):310-4. doi: 10.1097/CAD.0b013e32835c401c.